ISMPP Highlights
GPP4 – The Latest Update as Interest Grows
Excitement is building as the fourth iteration of the Good Publication Practice (also known as GPP4) guidance nears completion. At the 2022 European Meeting of ISMPP in late January, Dan Bridges (CEO, Nucleus Global) of the GPP4 Steering Committee presented information on the team’s progress. Watch the video to view this GPP4 update…
Building an ISMPP Educational Plan to Move Us All Forward
ISMPP consistently provides foundational educational resources for medical publication and communication professionals worldwide. To ensure alignment with the future educational needs of our members and to inform development of a longer-term, dynamic educational plan, the ISMPP Education Task Force launched a needs assessment survey in Q1 2021…
ISMPP-Sponsored Study on PLS Now Published in CMRO Presents Expert Perspectives
A new paper from the ISMPP PLS Perspectives Working Group has been published in Current Medical Research & Opinion. The paper presents findings from an ISMPP-sponsored, evidence-based study reporting on expert stakeholder perspectives to inform best practices for plain language summaries (PLS)…
Message from Our Leadership
Robert J. Matheis
ISMPP President and CEO
News and Trends
THE FUTURE OF ADVISORY BOARDS – Is This the End of the In-Person Format?
When writing The MAP article, “Advisory Boards: Words of Advice and a 10-point Checklist”, released in March 2020, we could not have predicted the era of unprecedented change that was to come. Many pharmaceutical companies had already been reaping the benefits of fully virtual advisory boards pre-COVID-19, but the necessity to move all meetings to a fully online format required a significant shift in strategy and mindset…
The Public Face of Science: Elevating Trust through Medical Communications – Continuing the Conversation
In any relationship, whether business or personal, transparency breeds trust. Today, despite the life science industry delivering unprecedented vaccine solutions to address the Covid pandemic, mistrust remains engrained in the public persona. Third parties have leveraged that doubt for their own gain…
A Snapshot into Medical Affairs
What does a Medical Affairs team look like at a pharmaceutical/biotechnology company? Is it like a bag of M&M’S® with similar functions, or is it unique from company to company, like a fingerprint? We conducted a survey of ISMPP members in March 2021, that provides insights into what comprises Medical Affairs at pharmaceutical/biotechnology companies…
What Would You Do?
In our role as medical publication professionals, we may occasionally encounter situations in which it is not obvious how to ensure good publication practice. Have you ever wished you could consult the ISMPP membership for guidance when these situations arise? Here’s your opportunity!
What Would You Do? is a section of The MAP that presents case scenarios as an educational tool for medical publication professionals. The section provides a case scenario to ponder, and readers are invited to participate in a poll by selecting one of the listed solutions. Readers can also submit their thoughts on the scenario anonymously. The poll results, plus educational insights, are posted in a later issue for readers to digest.
POLL RESULTS: Proceed with Data & Author Changes to a 2-year-old Manuscript?
You are the medical writer on a real-world evidence (RWE) manuscript that was initiated 2 years ago. At first draft stage, the project was put on hold. The lead author would like to perform additional analyses and include one of their colleagues as an author. Meanwhile, the new project owner/client would like to finalize and submit the article as soon as possible. What would you do?
ISMPP (pronounced IzMap) is the only nonprofit organization founded by medical publication professionals for medical publication professionals